Host Dysregulation-Driven Sepsis Prediction Model

NCT ID: NCT06523075

Last Updated: 2024-10-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-09-01

Study Completion Date

2024-10-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to identify risk factors associated with sepsis and to construct a predictive model for sepsis. This will provide an objective theoretical and empirical foundation for the diagnosis, assessment, and management of sepsis in our country.The primary questions addressed are:

What are the risk factors for the development of sepsis? How do we improve the prognosis of sepsis?

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sepsis Group

Tumor Necrosis Factor

Intervention Type OTHER

This study is a retrospective observational study, with Tumor Necrosis Factor being one of the exposure factors under investigation.

Interleukin-1β

Intervention Type OTHER

This study is a retrospective observational study, with Interleukin-1β being one of the exposure factors under investigation.

Interleukin-12

Intervention Type OTHER

This study is a retrospective observational study, with Interleukin-12 being one of the exposure factors under investigation.

Interleukin-18

Intervention Type OTHER

This study is a retrospective observational study, with Interleukin-18 being one of the exposure factors under investigation.

Complement C3

Intervention Type OTHER

This study is a retrospective observational study, with Complement C3 being one of the exposure factors under investigation.

Complement C5

Intervention Type OTHER

This study is a retrospective observational study, with Complement C5 being one of the exposure factors under investigation.

Non-Sepsis Group

Tumor Necrosis Factor

Intervention Type OTHER

This study is a retrospective observational study, with Tumor Necrosis Factor being one of the exposure factors under investigation.

Interleukin-1β

Intervention Type OTHER

This study is a retrospective observational study, with Interleukin-1β being one of the exposure factors under investigation.

Interleukin-12

Intervention Type OTHER

This study is a retrospective observational study, with Interleukin-12 being one of the exposure factors under investigation.

Interleukin-18

Intervention Type OTHER

This study is a retrospective observational study, with Interleukin-18 being one of the exposure factors under investigation.

Complement C3

Intervention Type OTHER

This study is a retrospective observational study, with Complement C3 being one of the exposure factors under investigation.

Complement C5

Intervention Type OTHER

This study is a retrospective observational study, with Complement C5 being one of the exposure factors under investigation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tumor Necrosis Factor

This study is a retrospective observational study, with Tumor Necrosis Factor being one of the exposure factors under investigation.

Intervention Type OTHER

Interleukin-1β

This study is a retrospective observational study, with Interleukin-1β being one of the exposure factors under investigation.

Intervention Type OTHER

Interleukin-12

This study is a retrospective observational study, with Interleukin-12 being one of the exposure factors under investigation.

Intervention Type OTHER

Interleukin-18

This study is a retrospective observational study, with Interleukin-18 being one of the exposure factors under investigation.

Intervention Type OTHER

Complement C3

This study is a retrospective observational study, with Complement C3 being one of the exposure factors under investigation.

Intervention Type OTHER

Complement C5

This study is a retrospective observational study, with Complement C5 being one of the exposure factors under investigation.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with Infection or Suspected Infection

Exclusion Criteria

* Patients with Autoimmune Diseases
* Pregnant Women
* Patients with Advanced-Stage Cancer and Systemic Metastasis
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Second Affiliated Hospital of Wenzhou Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Xiue Ye

Wenzhou, Zhejiang, China

Site Status

The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University,

Wenzhou, Zhejiang, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SAHoWMU-CR2024-16-214

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

STUDY00015328: Sepsis Endotypes
NCT03146546 ENROLLING_BY_INVITATION
Assessing Immune Dysfunction in Sepsis
NCT07154615 NOT_YET_RECRUITING